Hypoglycemia News and Research RSS Feed - Hypoglycemia News and Research

Hypoglycemia, also called low blood glucose or low blood sugar, occurs when blood glucose drops below normal levels. Glucose, an important source of energy for the body, comes from food. Carbohydrates are the main dietary source of glucose.
Oral insulin could help prevent type 1 diabetes in high-risk children

Oral insulin could help prevent type 1 diabetes in high-risk children

Children at risk for type 1 diabetes, who were given daily doses of oral insulin, developed a protective immune response to the disease that researchers with the Barbara Davis Center for Childhood Diabetes at the University of Colorado Anschutz Medical Campus say could possibly lay the groundwork for a vaccine against the chronic illness. [More]
Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai Inc. and Arena Pharmaceuticals, Inc. today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as compared to the twice-daily immediate release formulation approved by the US Food and Drug Administration and marketed as BELVIQ. [More]
Glyxambi for Type 2 diabetes treatment now available by prescription across the U.S.

Glyxambi for Type 2 diabetes treatment now available by prescription across the U.S.

Glyxambi® (empagliflozin/linagliptin) tablets are now available by prescription in many leading chain and independent pharmacies across the U.S., including Walgreens and Rite Aid. [More]
Sanofi announces FDA approval of Toujeo insulin to improve glycemic control in people with diabetes

Sanofi announces FDA approval of Toujeo insulin to improve glycemic control in people with diabetes

Sanofi announced today that the U.S. Food and Drug Administration approved Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, to improve glycemic control in adults living with type 1 and type 2 diabetes. Toujeo is expected to be available in the U.S. at the beginning of Q2 2015. [More]
Study: Definitive indicator of diabetes control deceptively high in African-American children

Study: Definitive indicator of diabetes control deceptively high in African-American children

A new study confirms the findings of two earlier LSU Health New Orleans studies that the definitive indicator of diabetes control, the HbA1c, is deceptively high in African-American children. [More]
New type of engineered insulin could improve treatment for diabetes patients

New type of engineered insulin could improve treatment for diabetes patients

For patients with diabetes, insulin is critical to maintaining good health and normal blood-sugar levels. However, it's not an ideal solution because it can be difficult for patients to determine exactly how much insulin they need to prevent their blood sugar from swinging too high or too low. [More]
Helsinn begins elsiglutide Phase IIB trial for prevention of chemotherapy-induced diarrhea

Helsinn begins elsiglutide Phase IIB trial for prevention of chemotherapy-induced diarrhea

Helsinn Healthcare S.A. and Zealand Pharma A/S jointly announce that Helsinn has started a Phase IIB clinical dose-finding trial of elsiglutide for the prevention of chemotherapy-induced diarrhea (CID). The first patients out of a planned total of 600 patients with colorectal cancer treated with chemotherapy have been dosed in the trial. [More]
Isis announces top-line results from ISIS-PTP1B Rx Phase 2 study in type 2 diabetes patients

Isis announces top-line results from ISIS-PTP1B Rx Phase 2 study in type 2 diabetes patients

Isis Pharmaceuticals, Inc. announced today top-line results from a Phase 2 study of ISIS-PTP1B Rx in patients with type 2 diabetes. In the Phase 2 study patients treated with ISIS-PTP1B Rx achieved statistically significant reductions in body weight and hemoglobin A1c (HbA1c). [More]
Research findings may accelerate work to safely control diabetes

Research findings may accelerate work to safely control diabetes

For those with diabetes, managing blood sugar is a balancing act -- if blood sugar is too high it raises the risk for nerve damage, blindness, kidney failure, and heart trouble, and if too low it can lead to a seizure or unconsciousness. [More]
Mount Sinai study measures ability of artificial pancreas in preventing hypoglycemia in T1D patients

Mount Sinai study measures ability of artificial pancreas in preventing hypoglycemia in T1D patients

A newly launched clinical research study at the Icahn School of Medicine at Mount Sinai is examining whether an artificial pancreas (AP) can prevent too low blood sugar levels or hypoglycemia in patients with type 1 diabetes (T1D) as they sleep. People fast as they sleep and nighttime hypoglycemia can cause seizures, and coma or death in rare cases, among the more than three million Americans with type 1 diabetes. [More]
Researchers find genetic mutation that causes glycogen storage disease type IIIa in Inuit

Researchers find genetic mutation that causes glycogen storage disease type IIIa in Inuit

A team of Canadian and Japanese researchers has identified the genetic mutation responsible for glycogen storage disease type IIIa in Inuit in northern Quebec, Canada, in a study published in CMAJ (Canadian Medical Association Journal). [More]
Endocrinology Network offers up-to-date coverage of SGLT2 inhibitors

Endocrinology Network offers up-to-date coverage of SGLT2 inhibitors

UBM Medica US announces that Endocrinology Network, a leading online community for endocrinologists and other clinicians who treat patients with T2DM offers comprehensive and up-to-date coverage of the sodium glucose cotransporter 2 (SGLT2) inhibitors. [More]
FDA approves Novo Nordisk’s weight loss injection, Saxenda

FDA approves Novo Nordisk’s weight loss injection, Saxenda

Novo Nordisk today announced that the Food and Drug Administration (FDA) has approved the new drug application (NDA) for Saxenda® (liraglutide [rDNA origin] injection), the first once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management. [More]
Lilly, Adocia team up to develop BioChaperone Lispro insulin for treatment of diabetes

Lilly, Adocia team up to develop BioChaperone Lispro insulin for treatment of diabetes

Eli Lilly and Company and Adocia today announced a worldwide licensing collaboration focused on developing an ultra-rapid insulin, known as BioChaperone Lispro, for treatment in people with type 1 and type 2 diabetes. [More]
Findings show effective treatment for type 1 diabetes patients with severe hypoglycemia

Findings show effective treatment for type 1 diabetes patients with severe hypoglycemia

Type 1 diabetes (T1D) patients who have developed low blood sugar (hypoglycemia) as a complication of insulin treatments over time are able to regain normal internal recognition of the condition after receiving pancreatic islet cell transplantation, according to a new study led by researchers at the Perelman School of Medicine at the University of Pennsylvania, published online in Diabetes. [More]
Opioid tramadol can increase hospitalization risk for hypoglycemia

Opioid tramadol can increase hospitalization risk for hypoglycemia

The opioid pain-reliever tramadol appears to be associated with an increased risk of hospitalization for hypoglycemia, a potentially fatal condition caused by low blood sugar, according to a report published online by JAMA Internal Medicine. [More]
External artificial pancreas improves glucose control, reduces hypoglycemia risk

External artificial pancreas improves glucose control, reduces hypoglycemia risk

The world's first clinical trial comparing three alternative treatments for type 1 diabetes was conducted in Montréal by researchers at the IRCM and the University of Montreal, led by endocrinologist Dr. Rémi Rabasa-Lhoret. [More]
New findings could help develop therapeutic options for glycogen storage disease

New findings could help develop therapeutic options for glycogen storage disease

Glycogen storage disorders, which affect the body's ability to process sugar and store energy, are rare metabolic conditions that frequently manifest in the first years of life. Often accompanied by liver and muscle disease, this inability to process and store glucose can have many different causes, and can be difficult to diagnose. [More]
Promising results for low-dose insulin in paediatric diabetic ketoacidosis

Promising results for low-dose insulin in paediatric diabetic ketoacidosis

Results of a randomised trial suggest that low-dose insulin may be at least as good as standard-dose insulin for the treatment of children with diabetic ketoacidosis. [More]
Economic impact of hypoglycaemia: an interview with Dr Klaus Henning Jensen

Economic impact of hypoglycaemia: an interview with Dr Klaus Henning Jensen

Hypoglycaemia is the term used to describe a lower than normal blood sugar level. There are a number of things that actually need to be formally defined in order for a hypoglycaemic episode to be diagnosed. [More]
Advertisement